IL31 and Alzheimer disease: A novel therapeutic strategy for targeting pruritus and inflammation, and restoring of the damaged skin barrier associated with AD, is the use of Nemolizumab, an anti–IL-31 receptor humanized monoclonal antibody that was developed for targeting IL-31RA receptors, inhibiting binding between IL-31 and IL-31RA [129].